ELDN

Company Overview — What Does Eledon Pharmaceuticals, Inc. Do?

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Eledon Pharmaceuticals, Inc. (ELDN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David-Alexandre C. Gros and employs approximately 10 people, headquartered in Cambridge, California. With a market capitalization of $228M, ELDN is one of the notable companies in the Healthcare sector.

Eledon Pharmaceuticals, Inc. (ELDN) Stock Rating — Reduce (April 2026)

As of April 2026, Eledon Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 26.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ELDN ranks #2,436 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Eledon Pharmaceuticals, Inc. ranks #302 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ELDN Stock Price and 52-Week Range

Eledon Pharmaceuticals, Inc. (ELDN) currently trades at $3.13. The stock gained $0.03 (1.0%) in the most recent trading session. The 52-week high for ELDN is $4.60, which means the stock is currently trading -32.0% from its annual peak. The 52-week low is $1.35, putting the stock 131.9% above its annual trough. Recent trading volume was 971K shares, suggesting relatively thin trading activity.

Is ELDN Overvalued or Undervalued? — Valuation Analysis

Eledon Pharmaceuticals, Inc. (ELDN) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 5.53x, compared to the Healthcare sector average of 23.63x — a discount of 77%. The price-to-book ratio stands at 2.85x, versus the sector average of 2.75x.

At current multiples, Eledon Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Eledon Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Eledon Pharmaceuticals, Inc. (ELDN) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 51.5%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 24.7% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ELDN Debt, Balance Sheet, and Financial Health

Eledon Pharmaceuticals, Inc. has a debt-to-equity ratio of 40.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 7.40x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $4M.

ELDN has a beta of 1.45, meaning it is more volatile than the broader market — a $10,000 investment in ELDN would be expected to move 44.7% more than the S&P 500 on any given day. The stability factor score for Eledon Pharmaceuticals, Inc. is 23/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Eledon Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Eledon Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.52. Net income for the quarter was $42M. Operating income came in at $-82M.

In FY 2025, Eledon Pharmaceuticals, Inc. reported revenue of N/A and earnings per share (EPS) of $-0.52. Net income for the quarter was $-46M.

In Q3 2025, Eledon Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.21. Net income for the quarter was $-17M. Operating income came in at $-19M.

In Q2 2025, Eledon Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.13. Net income for the quarter was $-11M. Operating income came in at $-25M.

Over the past 8 quarters, Eledon Pharmaceuticals, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing ELDN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ELDN Dividend Yield and Income Analysis

Eledon Pharmaceuticals, Inc. (ELDN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ELDN Momentum and Technical Analysis Profile

Eledon Pharmaceuticals, Inc. (ELDN) has a momentum factor score of 42/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 7/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ELDN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Eledon Pharmaceuticals, Inc. (ELDN) ranks #302 out of 838 stocks based on the Blank Capital composite score. This places ELDN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ELDN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ELDN vs S&P 500 (SPY) comparison to assess how Eledon Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

ELDN Next Earnings Date

No upcoming earnings date has been announced for Eledon Pharmaceuticals, Inc. (ELDN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ELDN? — Investment Thesis Summary

The quantitative profile for Eledon Pharmaceuticals, Inc. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. High volatility (stability score 23/100) increases portfolio risk.

In summary, Eledon Pharmaceuticals, Inc. (ELDN) earns a Reduce rating with a composite score of 26.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ELDN stock.

Related Resources for ELDN Investors

Explore more research and tools: ELDN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ELDN head-to-head with peers: ELDN vs AZN, ELDN vs SLGL, ELDN vs VMD.